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Abstract: Transporters belonging in the ATP-binding cassette (ABC) family are crucially involved in the determination 
of the pharmacokinetic behavior of xenobiotics and in the development of drug resistance. The targeting of these trans-
porters has been accepted as a rational option via which to modify the absorption or distribution of pharmaceutical agents 
and to combat ABC-related inefficiency. Inhibitors of the breast cancer resistance protein (BCRP/ABCG2) multidrug 
transporter are of interest as chemosensitizers for clinical drug resistance, for improving the pharmacokinetics of substrate 
chemotherapeutic drugs, and in functional assays of BCRP activity for tailoring chemotherapy. In this study, a reverse-
phase high-performance liquid chromatographic method was developed for the determination of a simplified fumi-
tremorgin C analog, Ko134, a potent ABCG2 inhibitor, in murine serum. The assay involves a simple sample preparation 
step followed by chromatographic separation on a C8 reversed-phase analytical column. The calibration plots were linear 
over the range 0.1 to10 μg/ml (r > 0.99). The limits of detection and quantification were 10 ng/ml and 50 ng/ml, respec-
tively. The validation results demonstrated that the method is precise, accurate and selective for the determination of 
Ko134 in mouse serum. The method was successfully applied to evaluate the pharmacokinetic parameters of Ko134 after 
different modes of administration in mice.  
Keywords: Drug administration, HPLC, Ko134, mouse serum, pharmacokinetics, validation. 
1. INTRODUCTION 
The ATP-binding cassettes (ABCs) are the largest family 
of transmembrane proteins and have been at the center of 
interest for many years. As primary active transporters, these 
proteins translocate a wide variety of substrates, including 
metabolic products, nutrients and drugs across extra- and 
intracellular membranes at the expense of ATP hydrolysis. 
The members of the family are encoded by 48 genes in hu-
mans, but only around 9 of them have a substantial impact 
on the pharmacokinetic behavior of drugs [1]. One of these 
crucial ABCs is the breast cancer resistance protein 
(BCRP/ABCG2), identified in 1998 in a resistant variant of 
breast cancer cell line MCF-7 [2]. ABCG2, also known as 
the placenta-specific ABC transporter (ABCP) [3] or mi-
toxantrone-resistance gene [4], is expressed in stem cells in 
all of the major tissues of the body [5], but is principally 
localized to the apical surface of the intestinal enterocytes, 
the luminal surface of the liver canaliculi and the proximal 
convoluted tubule of the kidneys and the blood–brain, 
blood–testis, blood–placental and blood–retinal barriers [6]. 
BCRP functions as a defense mechanism in human physiol-
ogy by limiting the absorption of pharmaceutical agents and 
toxic substrate molecules and also plays an active role in the 
secretion of drugs and xenobiotics by facilitating excretion. 
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Since BCRP is located on the secretory surface of the ma-
jor organs involved in the absorption (the small intestine), 
distribution (the placenta and various barriers) and elimina-
tion (the liver and small intestine) of drugs, it alters the 
bioavailability and pharmacokinetics of substrate drugs. 
Functional characterization has demonstrated that BCRP 
can transport a wide range of substrates, such as common 
dietary xenobiotics and chemotherapeutics, including mi-
toxantrone, topotecan, doxorubicin [7], daunorubicin [8], 
danusertib [9], irinotecan and its SN-38 metabolite [10] and 
imatinib [11].  
Besides ABCB1 and ABCC1, ABCG2 is one of the pro-
teins that is overexpressed upon exposure to toxic com-
pounds responsible for the development of multidrug resis-
tance. The expression of BCRP has been detected in nu-
merous types of human cancers, including hematological 
malignancies and solid tumors. The phenomenon of 
multidrug resistance is one of the major problems faced by 
anticancer chemotherapy. Based on their crucial biological 
functions all kinds of uptake and efflux transporters repre-
sent attractive targets for drug discovery with a broad vari-
ety of indications [12, 13]. The development of highly spe-
cific inhibitors of BCRP as chemosensitizers could improve 
the pharmacokinetics and therefore the efficacy of substrate 
chemotherapeutic drugs. The mycotoxin fumitremorgin C 
(FTC), isolated from Aspergillus fumigatus, was identified 
as a specific reversal agent for the BCRP transporter [14, 
15], but it exhibited toxic effects on the central nervous 
system inducing tremor activity in mice and other animals 
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[16]. The simplified FTC analog Ko134 (Fig. 1) has a much 
more potent ABCG2 inhibitory effect than that of FTC it-
self with improved selectivity and specificity, while dis-
playing low in vivo toxicity [17, 18]. Ko134 is therefore a 
commonly utilized reference compound in in vitro studies. 
However, since its pharmacokinetic profile is poorly char-
acterized, it has been inadequately evaluated in in vivo set-
tings. We are not aware of any analytical method that has 
been developed and validated for measurement of the con-
centration of Ko134 in animal serum. In this study, there-
fore, we developed and validated a sensitive HPLC assay 
with which to quantify Ko134 in mouse serum, and used 
this assay to characterize the basic pharmacokinetic pa-
rameters of Ko134 in mice. 
2. EXPERIMENTAL 
2.1. Chemicals and Materials 
Ko134 (3-[(3S,6S,12aS)-6-isobutyl-1,4-diketo-2,3,6,7,12, 
12a-hexahydropyrazino[1,2-b]--carbolin-3-yl]propionic 
acid tert-butyl ester) was synthetized as published previously 
[19]. 1-Isobutyl-2,3,4,9-tetrahydro-1H--carboline-3-carbo-
xylic acid acetate (internal standard, IS) was purchased from 
Sigma-Aldrich (Budapest, Hungary). Their chemical struc-
tures are illustrated in (Fig. 1). Potassium dihydrogenphos-
phate of analytical grade was obtained from Molar Chemi-
cals (Budapest, Hungary). Orthophosphoric acid of HPLC 
grade was from Sigma-Aldrich (Budapest, Hungary). HPLC-
grade acetonitrile and methanol were purchased from Merck 
(Darmstadt, Germany). The water was puried and deionized 
with a Milli-Q system (Millipore, Milford, MA, USA). All 
other chemicals were of analytical grade and were purchased 
from Sigma-Aldrich (Budapest, Hungary). 
2.2. Instrumentation 
The HPLC apparatus consisted of a Shimadzu system 
(Shimadzu Corporation, Kyoto, Japan) equipped with a sol-
vent delivery system (LC-20AD), a DGU-20A3 on-line de-
gasser, a CTO-20A column oven, an SPD-M20A photodi-
ode-array detector, an RF-10A XL uorescence detector and 
a CBM-20A system controller. The chromatographic system 
was involved a Rheodyne Model 7125 injector (Cotati, CA, 
USA) with a 20-μl loop. The system control and data acqui-
sition were performed with Shimadzu “LC solution” soft-
ware (Shimadzu Corporation, Kyoto, Japan). 
2.3. Liquid Chromatographic Conditions 
The chromatographic separations were performed on a 
Kromasil KR100-5C8-150A 5-μm, 250-mm  4.6-mm ana-
lytical column (Hichrom, Berkshire, UK), protected by a 5 
μm Kromasil C8 guard column. The column temperature 
was kept constant at 35 ºC. Separations were performed in 
isocratic mode. The mobile phase used for the separation 
consisted of 0.025 M potassium dihydrogenphosphate buffer 
(pH 2.7):acetonitrile (50:50, v/v) pumped at a ow rate of 
0.8 ml/min. The mobile phase was ltered by a Millipore 
vacuum ltration system equipped with a 0.45-μm pore size 
lter and degassed by ultrasonication. The uorescence de-
tector was set at 235 nm as excitation wavelength and 300 
nm as emission wavelength.  
2.4. Preparation of Stock and Working Solutions 
Primary stock solutions of Ko134 and the IS were pre-
pared in a concentration of 0.5 mg/ml in acetonitrile. The 
stock solution of Ko134 was further diluted in acetonitrile 
to obtain an intermediate concentration of 50 μg/ml. The 
working standard solutions of Ko134 (1–50 μg/ml) re-
quired for serum spiking and quality control (QC) samples 
were subsequently obtained by dilution from the primary 
and intermediate stock solutions. The 0.5 mg/ml stock solu-
tion of the IS was further diluted with acetonitrile to yield a 
working solution of 0.05 mg/ml. All acetonitrile solutions 
were stored at 20 ºC, protected from the light, until used. 
2.5. Preparation of Calibration and Quality Control 
Standards 
Drug-free control mouse serum was spiked with portions 
of working standard solutions of Ko134 to provide calibra-
tion standards in the range 0.1–10 μg/ml. QC samples were 
prepared by spiking drug-free control mouse serum with 
working standard solutions to provide samples at three dif-
ferent concentrations of Ko134, low (LQC = 0.2 μg/ml), 
medium (MQC = 5 μg/ml) and high (HQC = 8 μg/ml), from 
a weighing independent of those used for preparing the cali-
bration curves. Aliquots (0.2 ml) from the bulk QC solutions 
were transferred into Eppendorf tubes and stored at 20 ºC 
until analysis. 
2.6. Serum Sample Pretreatment 
Mouse serum samples were fully thawed at room tem-
perature and vortexed adequately. Aliquots of mouse serum 
(0.2 ml) were spiked with 20 μl of the IS solution (0.05 
mg/ml) and mixed with 1.2 ml of methanol to precipitate the 
proteins, vortexed for 1 min and centrifuged for 10 min at 
12,000 g. The supernatants were transferred to a set of clean 
glass tubes and evaporated to dryness under a stream of ni-
trogen at 40 ºC. Each residue was reconstituted in 200 μl of 
mobile phase and vortex-mixed for 10 s; 20 μl of solution 
was injected for analysis. 
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Fig. (1). Chemical structures of Ko134 (A) and 1-isobutyl-2,3,4,9-tetrahydro-1H--carboline-3-carboxylic acid acetate (B). 
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2.7. Validation of the Method 
The HPLC method was validated according to the guide-
lines for bioanalytical method validation laid down by the 
FDA [20]. 
2.7.1. Specificity and Selectivity 
The specificity and selectivity of the method were as-
sessed by screening different sources of blank mouse serum 
for endogenous interferences in the retention time of Ko134. 
Chromatograms of blank samples were compared with those 
of serum samples spiked with Ko134 and IS, and serum 
samples obtained from mice after the administration of 
Ko134.  
2.7.2. Linearity 
The linearity range of the method for Ko134 in serum 
was evaluated by means of seven-point standard plots in the 
concentration range 0.1–10 μg/ml on three validation days. 
Serum calibration curves were constructed by plotting the 
peak area ratio of Ko134 against the IS peak area vs. analyte 
concentration using linear regression. The calibration curves 
were evaluated from the aspects of their correlation 
coefcients, slopes and intercepts. Analysis of variance 
(ANOVA) was used to assess significant differences at 5% 
significance level. The data analysis MS Excel software 
(2007) was employed in all statistical analyses of calibration. 
The calibration curves were evaluated from the aspects of 
their correlation coefcients, slopes and intercepts. The con-
centrations at the limit of detection (LOD) and the lower 
limit of quantitation (LOQ) were empirically determined 
during the evaluation of the linear range of the calibration 
curve [21]. The LOD of an individual analytical procedure is 
the lowest amount of analyte in a sample that can be de-
tected, but not necessarily quantitated as an exact value. The 
LOQ is the lowest amount of analyte in a sample that can be 
quantitatively determined with a precision with CV less than 
20% and accuracy within 15% of the nominal value. The 
accuracy of calibration standards was required to be within ± 
15% of the nominal concentration, except at the LOQ, where 
it was required to be within ± 20%. 
2.7.3. Precision and Accuracy 
The intra-day precision and accuracy of the method for 
the quantification of Ko134 were determined by analysis of 
five sets of serum QC samples at the LQC, MQC and HQC 
levels in a single day. The inter-day precision and accuracy 
were estimated by analysis of all QC samples over five vali-
dation days. Accuracy was calculated as the mean percentage 
deviation (RE) of the observed concentration (Cobs) from the 
nominal concentration (Cnom) at each QC level: %RE = 
[(Cobs-Cnom)/Cnom] x 100. Precision was expressed as a per-
centage of the coefficient of variation: %CV = (SD/mean 
Cobs) x 100. The criteria for acceptability were that the intra- 
and inter-assay accuracies and precisions should be within ± 
20% at the LOQ level and within ± 15% at other concentra-
tions. 
2.7.4. Recovery 
The recovery from serum was carried out in QC samples 
at the LQC, MQC and HQC levels. The absolute percentage 
recovery was determined by comparing the mean peak area 
of three replicates of MeOH-treated samples with the mean 
peak areas of non-treated standards of equivalent concentra-
tion: %AR = (peak area sample/peak area standard) x 100.  
2.7.5. Stability 
The freeze–thaw stability of Ko134 in mouse serum was 
evaluated through the use of QC samples at three concentra-
tion levels, which were maintained at the storage temperature 
(–70 ºC) for 24 h and then thawed at room temperature. 
When completely thawed, the samples were refrozen for 24 
h under the same conditions. The freeze–thaw cycles were 
repeated three times before sample preparation and analysis.  
For the short-term stability study, QC serum samples 
were kept at room temperature for a period that exceeded the 
routine preparation time of the samples (24 h). The long-
term stability of Ko134 in mouse serum was assessed by 
analyzing QC samples stored at –70 ºC for 1 month. The 
stability of the Ko134 stock solution was evaluated at room 
temperature for 3 days.  
The peak areas of Ko134 at the initial concentrations at 
different QC levels were used as reference to determine the 
relative stability of Ko134 in the experiments described 
above. 
2.8. Pharmacokinetic Study 
The pharmacokinetic study was carried out with male 
CFLP mice (Toxi-Coop, Budapest, Hungary) aged 6 weeks, 
weighing 24-30 g, which were allowed to acclimate for 1 
week before the study. The animals were fasted overnight 
(~16 h) before drug administration, but had free access to 
water throughout the experimental period. They were given 
standard rodent food (Bioplan, Isaszeg, Hungary) 2 h after 
drug administration. The mice were randomized into 3 
groups of 5 animals each for the different treatments. Group 
1 was treated with a 30 mg/kg intravenous (iv) bolus of 
Ko134 in a solvent system via the tail vein; the mice in 
Group 2 received 50 mg/kg Ko134 orally by gavage; and 
Group 3 received the dose of 50 mg/kg intraperitoneally (ip). 
The solvent system in which Ko134 was dissolved was 90% 
physiological saline, 5% Cremophor, 5% dimethylsulfoxide 
and all treatments were administered in a dosing volume of 
10 ml/kg. 15, 30, 60, 120 and 240 min after the Ko134 
treatment, the mice were anesthetized with isoflurane, and 
blood was collected by cardiac puncture and centrifuged at 
5000 g for 10 min to obtain serum. Additional samples were 
collected 20 and 45 min after the ip administration. Samples 
were stored at –70 °C until analysis. All experiments involv-
ing animal subjects were carried out with the approval of the 
Hungarian Ethics Committee for Animal Research (registra-
tion number: IV/01758-2/2008). 
2.9. Data Analysis 
The figures of HPLC chromatograms were produced us-
ing gnuplot 4.6 (Ubuntu 12.04), the pharmacokinetic pa-
rameters were calculated by means of PKSolver using non-
compartmental analyses module [22]. The data analysis 
module of MS Excel 2007 was used to perform ANOVA 
analysis of the HPLC calibration. One-way ANOVAs were 
used to test if the slopes were significantly different from 
zero, with the level of significance set at p<0.05. 
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3. RESULTS AND DISCUSSION 
3.1. Development of the Chromatographic Conditions 
HPLC separations were initially tested on two types of 
reversed phase columns, an ACE C8 (250 mm  4.6 mm, 5 
μm; Advanced Chromatography Technologies, Aberdeen, 
Scotland) and a Kromasil C8 (250 mm  4.6 mm, 5 μm, 
Hichrom, Berkshire, UK) analytical column with mixtures of 
phosphate buffer at pH 2.7 and MeCN as eluents. The Kro-
masil column provided better peak shapes/symmetry com-
bined relatively shorter retention times and was used for fur-
ther analysis. The best chromatographic condition was ob-
tained with 0.025 M potassium dihydrogenphosphate buffer 
(pH 2.7):MeCN (50:50, v/v) at a flow rate of 0.8 ml/min. 
The UV-vis absorbance of Ko134 was recorded from wave-
lenght of 190-800 nm with the Shimadzu SPD-M20A photo-
diode-array detector. The absorption maximums of Ko134 
were at 223 nm and 274 nm. Therefore, wavelenght of 235 
nm was chosen for UV detection in this assay. After depro-
teinization of serum samples, the sensitivity at the optimal 
UV wavelenght would not be sufficient because of the low 
concentration of Ko134 in mice, thus fluorescence detection 
was selected for this study. As the absorptium maximum is 
almost identical with the excitation maximum of the analyte, 
the excitation wavelenght is typically choosen close to the 
absorption maximum, namely 225 nm. An excellent fluores-
cent yield was acquired at 300 nm, selected as the optimal 
emission wavelenght. In summary, the best chromatographic 
condition was obtained with 0.025 M potassium dihydrogen-
phosphate buffer (pH 2.7):MeCN (50:50, v/v) pumped at 
ow rate of 0.8 ml/min using a Kromasil KR100-5C8-150A 
(5 μm, 250 mm  4.6 mm) analytical column (Hichrom, 
Berkshire, UK), with fluorescence detection at excitation 
wavelenght of 235 nm and emission wavelenght of 300 nm, 
temperature at 35 °C [23].  
3.2. Specificity and Selectivity 
The analysis of drug-free serum from six individual 
blank samples revealed that there were no interfering peaks 
of endogenous substances at the retention times of Ko134 
and the IS, indicating the specificity of the method. With the 
chromatographic system described, the retention times for 
Ko134 and the IS were 16.04 ± 0.5 min and 14.41 ± 0.4 min, 
respectively. (Fig. 2) represents chromatograms of blank 
mouse serum, serum spiked with the IS and Ko134, and an 
experimental mouse serum sample collected 30 min after iv 
treatment with 30 mg/kg of Ko134.  
3.3. Linearity 
Seven-point calibration plots were constructed for Ko134 
at concentrations of 0.1, 0.2, 0.5, 1, 2, 5 and 10 μg/ml for 
three consecutive days. Under the described chroma-
tographic conditions, a linear relationship with a good corre-
lation coefficient (r=0.9969 ± 0.0031, n=3) was found be-
tween the peak area ratio of Ko134 against the IS peak area 
vs. analyte concentration in the calibration concentration 
range. The regression equation of the calibration plot was y = 
1245280.35x ± 10916, the relative standard deviation of the 
slope was 1.30 % (ANOVA; P<0.05). The LOQ, defined as 
the quantity that was 10-fold above the background noise 
and that could be determined with acceptable precision and 
accuracy, was found to be 50 ng/ml for Ko134 in mouse se-
rum samples. The mean percentage accuracy was 95% and 
the precision was below 10%. The LOD was 10 ng/ml with a 
signal-to-noise ratio of 3. 
3.4. Precision and Accuracy 
The results relating to the accuracy and precision are 
shown in Table 1. The intra- and inter-day accuracies for 
Ko134 at the 0.2, 5 and 8 μg/ml levels in mouse serum fell in 
the ranges 94.30–106.9% and 95.1–101.24%, and the intra- 
and inter-day precisions (CV%) were in the ranges 4.6–9.3% 
and 7.1–8.9%, respectively. These data indicated that the 
repeatability, intermediate precision and bias values of the 
assay were within the acceptance limits of ±15% at all QC 
concentration levels, and the validated assay was therefore 
precise, accurate and reproducible. 
3.5. Recovery 
The mean extraction recoveries of Ko134 at concentra-
tions of 0.2, 5 and 8 μg/ml were 98.6 ± 2.0%, 100.5 ± 5.8% 
and 101.3 ± 4.7%, respectively (Table 1). The mean recovery 
of the IS was 96.7%, with CV = 1.8%. The results showed 
that there was no substantial difference in the signals of the 
analytes extracted from mouse serum and the non-extracted 
standard solutions.  
3.6. Stability 
Data on the stability of Ko134 during sample handling 
(freeze–thaw, short-term, long-term and stock solution) are 
given in Table 2. Ko134 at all QC levels was stable in mouse 
serum for at least 24 h at room temperature, during three 
freeze–thaw cycles, and during storage at –70 ºC for 1 
month. The high stability of Ko134 in mouse serum sug-
gested that no special care was needed during sample prepa-
ration and a large batch of samples could be processed at one 
time within 24 h, a situation satisfying the requirements of 
efficient and fast analysis.  
3.7. Pharmacokinetic Study of Ko134 in Mice 
The method described above was successfully applied to 
quantify the serum concentrations of Ko134 in the pharma-
cokinetic study after iv, oral or ip administration to mice. 
The mean serum concentration–time profiles are shown in 
(Fig. 3). The basic pharmacokinetic parameters of Ko134 in 
mice calculated with the PKSolver 2.0 software in the non-
compartmental approach [19] are listed in Table 3. As shown 
in (Fig. 3), the pharmacokinetic profile of Ko134 after the iv 
bolus injection (30 mg/kg) points to a first-order kinetic 
process in mice, with a two-phase exponential elimination 
suggesting its distribution in two compartments. After ip 
administration (50 mg/kg), Ko134 was rapidly absorbed; 
substantial serum concentrations were detected 20 min after 
injection and Tmax was found at 30 min. The compound is 
rapidly eliminated independently of the mode of delivery (t 
~40-60 min and CL ~66 ml/min), indicating the need for 
multiple administration when continuous blockade of the 
ABCG2 transporter is expected in mice. The calculated pa-
rameters suggest that Ko134 exhibits high clearance and a 
high volume of distribution in mice. Since the volume of 
distribution is substantially higher than the total water 
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Fig. (2). Representative chromatograms of blank mouse plasma (A); blank mouse serum spiked with 5 g/ml Ko134 and 5 g/ml IS (B); and 
a mouse serum sample at 30 min after a single iv administration of 30 mg/kg Ko134 spiked with 5 g/ml IS (C).  
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Table 1. Accuracy, precision and recovery of values of Ko134 QC samples in mouse serum. 
Spiked Ko134 Concentration (μg/ml)  
0.2 5.0 8.0 
Accuracy and precision    
Intra-day precision (n=5)    
Measured concentration (mean ± S.D.; μg/ml) 0.1886 ± 0.0176 5.2580 ± 0.4329 8.5590 ± 0.3988 
Accuracy (%) 94.3 105.1 106.9 
CV (%) 9.3 8.2 4.6 
Inter-day precision (n=5)    
Measured concentration (mean ± S.D.; μg/ml) 0.1902 ± 0.0171 5.0620 ± 0.4385 7.9460 ± 0.5708 
Accuracy (%) 95.1 101.2 99.3 
CV (%) 8.9 8.6 7.1 
Recovery    
Extraction recovery (mean ± S.D.; %) 98.6 ± 2.0 100.5 ± 5.8 101.3 ± 4.7 
CV (%) 2.0 5.7 4.6 
 
Table 2. Stability values of Ko134 samples under various experimental conditions. 
QC Sample (μg/ml) Stability Condition % Remaining ± S.D. 
3 freeze-thaw cycles 95.7 ± 4.5 
Short–term (room temperature, 24 h) 97.0 ± 9.4 
Long-term (-70 ºC, 30 days) 98.2 ± 3.5 
0.2 
Stock solution (room temperature, 3 days) 97.9 ± 6.8 
3 freeze-thaw cycles 98.3 ± 2.6 
Short–term (room temperature, 24 h) 100.2 ± 3.0 
Long-term (-70 ºC, 30 days) 102.4 ± 4.1 
5.0 
Stock solution (room temperature, 3 days) 105.0 ± 5.9 
3 freeze-thaw cycles 99.7 ± 4.0 
Short–term (room temperature, 24 h) 102.7 ± 2.2 
Long-term (-70 ºC, 30 days) 95.6 ± 3.6 
8.0 
Stock solution (room temperature, 3 days) 98.2 ± 5.3 
 
 
Fig. (3). Mean serum concentration–time profiles of Ko134 following a single intravenous (30 mg/kg), oral (50 mg/kg) (panel A) or intraperi-
toneal (50 mg/kg) (panel B) administration in male CFLP mice (mean ± SEM, n=5 for all). 
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Table 3. Calculated pharmacokinetic parameters of Ko134 in mice after different administration routes. 
Route of Administration 
Parameter 
Intravenous (30 mg/kg) Intraperitoneal (50 mg/kg) 
Lambda_z (1/min) 0.0168 0.0115 
AUC0–t (min µg/ml) 448.37 196.95 
AUC0–∞ (min µg/ml) 451.14 212.70 
T1/2 (min) 41.20 60.37 
CL (ml/min) 66.50 66.50 
Vd (ml) 3952.3 5792.28 
F (%) – 28.29 
Data were calculated by using noncompartmental analysis. Lambda_z: elimination constant; AUC0 → t: area under the concentration–time curve from time 0 to 240 min; AUC0 → ∞: 
area under the time–concentration curve from time 0 to infinity; T1/2 : elimination half-life; Vd: volume of distribution; CL: total clearance; F: absolute bioavailability calculated from 
AUC0→∞ values. 
 
content of the animal most of the given amount is concen-
trated out of intravascular compartment. The physiological 
bioavailability calculated from the AUC0→∞ values of ip in-
jected Ko134 is relatively low (28.29%), contraindicating 
this administration route in in vivo experimentation. Oral 
treatment with 50 mg/kg Ko134 did not result in consider-
able serum concentrations, presumably as a consequece of 
the limited intestinal absorption or the extensive presystemic 
or hepatic first-pass metabolism, and therefore no kinetic 
parameters were calculated for this mode of administration. 
CONCLUSION 
The validated HPLC method presented here is suitable 
for the determination of the reference compound Ko134 in 
mouse serum and presumably other body fluids. Its simplic-
ity and reliability make it ideal as a basis for the develop-
ment of analytical methods for the quantitation of Ko134 in 
solid tissues, including experimentally induced cancer. De-
termination of the appropriate iv or ip dosage schedule of 
Ko134 is facilitated by the calculated pharmacokinetic pa-
rameters. 
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